Dendritic Cell Immunotherapy

Aetna considers dendritic cell immunotherapy experimental/investigational and not covered for any indication (including the specified ICD‑10 malignant neoplasm codes and melanoma in situ); no specific CPT/HCPCS code is identified. Coverage would require completion of randomized trials and establishment of appropriate antigen(s), adjuvant(s), dose, route and schedule, which have not yet been defined.

"Although multiple clinical contexts are discussed in the Background (e."

Sign up to see full coverage criteria, indications, and limitations.